## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-06-16_Virtual Town Hall 60_fixnames.md
last updated: 2025-01-03 Created QA Sections
link pdf: https://www.fda.gov/media/150355/download
link youtube: https://youtu.be/59Ni_qSGAtc
link slides: 
topic: COVID-19


## content

### qa


#### 1. FDA Updates on SARS-CoV-2 Testing and Prioritization

QA Block 1-1
CLARIFIED QUESTION: What factors are being studied to determine how serology tests measure immunity or protection?
CLARIFIED ANSWER: The FDA is awaiting results from government-sponsored immunity and protection studies to identify reliable factors for determining immunity, such as specific antibody levels. Developers can perform their own studies, but large studies are usually required.
VERBATIM QUESTION: What factors are being studied to determine how serology tests measure immunity or protection?
VERBATIM ANSWER: We've had numerous inquiries about using serology to measure immunity and/or protection either from natural infection or following vaccines. This is a hot topic for our office. We are awaiting data from U.S. Government-sponsored immunity and protection studies to understand what are the factors that determine and can be relied on to make these assessments. You know, sponsors, test developers are free to generate that kind of information, although, it seems like it would take fairly large studies to see what a certain level of antibodies, for example, offers in the way of immunity because you are looking at outcomes. So, you know, as soon as we have definitive information about how to measure immunity and protection, we will be able to provide some more help to developers as far as what our recommendations are for validation of serology tests for this purpose.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology testing, Immunity measurements, Study requirements
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: How can test developers independently generate data on the effectiveness of antibody levels in providing immunity?
CLARIFIED ANSWER: Test developers may generate data on antibody effectiveness by conducting large studies to assess the link between antibody levels and immunity outcomes.
VERBATIM QUESTION: How can test developers independently generate data on the effectiveness of antibody levels in providing immunity?
VERBATIM ANSWER: Sponsors, test developers are free to generate that kind of information, although, it seems like it would take fairly large studies to see what a certain level of antibodies, for example, offers in the way of immunity because you are looking at outcomes.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Serology tests, Antibody immunity, Study requirements
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: What is the current priority focus of the FDA for COVID-19 diagnostic test development?
CLARIFIED ANSWER: The FDA's priorities for COVID-19 diagnostics include expanding testing access, emphasizing lower-cost options, over-the-counter and home diagnostic tests, high-throughput central lab tests, and point-of-care tests.
VERBATIM QUESTION: What is the current priority focus of the FDA for COVID-19 diagnostic test development?
VERBATIM ANSWER: Our current priorities remain the same. We are focusing on ways to expand testing opportunities, making it more accessible. We do think it's important that there are lower-cost opportunities. And so over-the-counter and home diagnostic tests and collection devices are our priorities, as are really high throughput diagnostic central lab tests and point of care tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 diagnostic priorities, Testing accessibility, Home and point-of-care tests
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: What is the FDA's recommendation for developers using the pre-EUA process?
CLARIFIED ANSWER: The pre-EUA process is optional and intended to align FDA's advice with developers' efforts, focusing on unique elements not covered by existing templates or prior public decisions.
VERBATIM QUESTION: What is the FDA's recommendation for developers using the pre-EUA process?
VERBATIM ANSWER: So we - you know, the pre-EUA process is not a required process. And it's designed to try to be helpful and make sure that we're aligned on what the recommendations are from the FDA. So test developers can, you know, not do something and find out it doesn't quite work. Developers are always able to go ahead and submit and do the work and submit their EUAs. However, there are certain things that, you know, that may not be known. So we really are hoping only to advise your pre-EUAs, those things that are unique and different from what are present in the template. So, you know, look at our prior decisions. Look at - that are public. And look at, you know, our templates. And hopefully, that meets the lion's share of pre-EUA requests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA process, FDA recommendations, test development
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: When might information from U.S. Government immunity and protection studies be available to the public?
CLARIFIED ANSWER: FDA is awaiting data from U.S. Government immunity and protection studies to determine key factors for assessments. The information will likely be made public in real-time, but the exact timing is unknown.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We are awaiting data from U.S. Government-sponsored immunity and protection studies to understand what are the factors that determine and can be relied on to make these assessments. So, you know, as soon as we have definitive information about how to measure immunity and protection, we will be able to provide some more help to developers as far as what our recommendations are for validation of serology tests for this purpose. So stay tuned. We can't - we don't know when that information is going to be made public. We expect we'll see it, you know, and pretty much real-time. And it will probably be made public pretty much in real-time as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Immunity and protection studies, Serology validation, Data availability timeline
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: How does the FDA plan to address the significant backlog in the pre-EUA process?
CLARIFIED ANSWER: The FDA is addressing the pre-EUA backlog by maintaining efficiency despite reduced staffing, prioritizing cases aligned with its templates, and advising developers to align submissions with public prior decisions and existing guidance. The pre-EUA process is optional and meant to help clarify unique submissions.
VERBATIM QUESTION: How does the FDA plan to address the significant backlog in the pre-EUA process?
VERBATIM ANSWER: We are still receiving a high volume of submissions for COVID. And however, we are keeping up with the volume even with reducing the surge, mainly to pre-surge, almost to pre-surge level as far as staffing goes. But we are staying ahead of it. We are closing out our files more quickly than we are receiving them. But there is still a bit of a backlog. In particular, the pre-EUA backlog is not insignificant. And Toby and I have been making recommendations on recent calls for certain callers to check-in through the pre-EUA process. So we - you know, the pre-EUA process is not a required process. And it's designed to try to be helpful and make sure that we're aligned on what the recommendations are from the FDA. So test developers can, you know, not do something and find out it doesn't quite work. Developers are always able to go ahead and submit and do the work and submit their EUAs. However, there are certain things that, you know, that may not be known. So we really are hoping only to advise your pre-EUAs, those things that are unique and different from what are present in the template. So, you know, look at our prior decisions. Look at - that are public. And look at, you know, our templates. And hopefully, that meets the lion's share of pre-EUA requests. We know that there's questions that don't quite neatly fall in the template. You know, it is our priority to get through those pre-EUAs. It's just that we have a significant number of submissions, as I said. And we're doing our best to work through them.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA workload, Pre-EUA backlog, Developer guidance
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: How can developers ensure their submissions align with the latest FDA recommendations and templates?
CLARIFIED ANSWER: FDA advises developers to use the pre-EUA process for unique scenarios, review public prior decisions, and follow available templates to ensure submissions align with recommendations.
VERBATIM QUESTION: How can developers ensure their submissions align with the latest FDA recommendations and templates?
VERBATIM ANSWER: The pre-EUA process is not a required process. And it's designed to try to be helpful and make sure that we're aligned on what the recommendations are from the FDA. So test developers can, you know, not do something and find out it doesn't quite work. Developers are always able to go ahead and submit and do the work and submit their EUAs. However, there are certain things that, you know, that may not be known. So we really are hoping only to advise your pre-EUAs, those things that are unique and different from what are present in the template. So, you know, look at our prior decisions. Look at - that are public. And look at, you know, our templates. And hopefully, that meets the lion's share of pre-EUA requests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: pre-EUA process, FDA templates, submission alignment
REVIEW FLAG: False


#### 2. Safety and Approval of Hazardous Chemicals in Tests

QA Block 2-1
CLARIFIED QUESTION: Once the COVID-19 emergency has been lifted, will FDA entertain the use of pooling in cleared FDA devices intended to detect SARS-CoV-2?
CLARIFIED ANSWER: FDA will consider the use of pooling in cleared devices for SARS-CoV-2 detection, provided appropriate validation data and a positive benefit-risk analysis are included in the 510k submission.
VERBATIM QUESTION: Once the COVID-19 emergency has been lifted, will FDA entertain the use of pooling in cleared FDA devices intended to detect SARS-CoV-2?
VERBATIM ANSWER: Yes. We would consider that. The type of claim for pooling would need to be supported by appropriate validation data and a positive benefit-risk analysis. So we would ask that you include that in your 510k submission. And we are open to considering proposals for that.
SPEAKER QUESTION: Toby Lowe (FDA IVD Assoc Director)
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: FDA device clearance, Pooling for SARS-CoV-2 detection, Post-COVID-19 emergency policies
REVIEW FLAG: False

QA Block 2-2
CLARIFIED QUESTION: Will FDA consider clearance for tests that are indicated for both individual and pooled specimen testing?
CLARIFIED ANSWER: FDA will consider clearance for tests indicated for both individual and pooled specimen testing, provided appropriate validation data and benefit-risk analysis are submitted with a 510(k) submission.
VERBATIM QUESTION: Will FDA consider clearance for tests that are indicated for both individual and pooled specimen testing?
VERBATIM ANSWER: Yes. We would consider that. The type of claim for pooling would need to be supported by appropriate validation data and a positive benefit-risk analysis. So we would ask that you include that in your 510k submission. And we are open to considering proposals for that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Pooling in diagnostics, Test clearance
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: Is it true that an over-the-counter molecular test should not include a hazardous substance?
CLARIFIED ANSWER: The FDA prefers that no hazardous materials are used in at-home tests, but recognizes that developers may need to include such substances in diluted forms. The FDA conducts toxicology reviews and encourages submission of documentation confirming whether chemicals used are hazardous at the concentrations in question. Mitigations like labeling and safety measures are considered when necessary.
VERBATIM QUESTION: Is it true that an over-the-counter molecular test should not include a hazardous substance?
VERBATIM ANSWER: Oh yes. So we have seen the use of hazardous chemicals in the development of certain tests. These typically fall into three different categories or uses. One is preservatives to prevent microbial growth in buffers. There are materials that are used to lyse cells or virus. And then there are materials to stabilize RNA. And as we began authorizing at-home tests and at-home collection devices, it became clear to us that this was an important review for the FDA to do. We would prefer that no hazardous materials enter the home. And if there are potential hazardous materials that they're of the type, that a dilute version of them as is the case in many examples, for example, detergents are usually in very low percent. It's only in high concentrations of detergent that, you know, say it splashes into the eye or could potentially cause harm to the patient. Others, some preservatives such that are being used, you know, are potentially hazardous substances. So we, in an effort to make testing as widely available, we know that developers sometimes cannot avoid some of these components. So we do a Hazardous Chemical Substance Toxicology Review. We encourage developers to, you know, to submit documentation that says, you know, whether or not the chemicals that are in their test are hazardous, especially at the concentrations that are being used in the test. So a number of these reviews have happened. And we look at. And some of them have turned out to be safe to use without special considerations, mainly because they're fairly dilute. But we continue this review. And we ask that developers send MSDS sheets, literature studies. You know, in particular, the literature studies look at lower concentrations of some of these chemicals. MSDS largely looks at the undiluted forms and in many cases, the MSDS's are not appropriate for full hazard analysis. We look at, you know, if there is something that still remains in a range where it may not be entirely safe, we look at other mitigation, such as wearing gloves or eye protection. We prefer not to have to go that route. We also look at labeling, very strong labeling. So, yes, we would prefer that non-toxic materials are used. We know that in the effort to get tests out there that it may not be possible to move away from them at this time. So we just look for mitigations. And we look at the available data to make the best decisions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Hazardous substances in tests, FDA toxicology review, At-home test safety
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: Does the restriction on hazardous substances for over-the-counter tests also apply to antigen tests, or just to molecular tests?
CLARIFIED ANSWER: The FDA prefers no hazardous chemicals in tests for over-the-counter use but recognizes their necessity in some cases, including in both antigen and molecular tests. A review process mitigates risks by evaluating safety documentation.
VERBATIM QUESTION: Does the restriction on hazardous substances for over-the-counter tests also apply to antigen tests, or just to molecular tests?
VERBATIM ANSWER: So we have seen the use of hazardous chemicals in the development of certain tests. These typically fall into three different categories or uses. One is preservatives to prevent microbial growth in buffers. There are materials that are used to lyse cells or virus. And then there are materials to stabilize RNA. And as we began authorizing at-home tests and at-home collection devices, it became clear to us that this was an important review for the FDA to do. We would prefer that no hazardous materials enter the home. And if there are potential hazardous materials that they're of the type, that a dilute version of them as is the case in many examples, for example, detergents are usually in very low percent. It's only in high concentrations of detergent that, you know, say it splashes into the eye or could potentially cause harm to the patient. Others, some preservatives such that are being used, you know, are potentially hazardous substances. So we, in an effort to make testing as widely available, we know that developers sometimes cannot avoid some of these components. So we do a Hazardous Chemical Substance Toxicology Review. We encourage developers to, you know, to submit documentation that says, you know, whether or not the chemicals that are in their test are hazardous, especially at the concentrations that are being used in the test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Hazardous substances in tests, Regulatory review, Over-the-counter testing
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: What are acceptable forms of evidence or documentation to demonstrate that chemicals in a test are non-hazardous?
CLARIFIED ANSWER: The FDA asks developers to submit MSDS sheets and literature studies as documentation for determining whether chemicals in their test are hazardous, especially at the specific concentrations used.
VERBATIM QUESTION: What are acceptable forms of evidence or documentation to demonstrate that chemicals in a test are non-hazardous?
VERBATIM ANSWER: We encourage developers to, you know, to submit documentation that says, you know, whether or not the chemicals that are in their test are hazardous, especially at the concentrations that are being used in the test. So a number of these reviews have happened. And we look at. And some of them have turned out to be safe to use without special considerations, mainly because they're fairly dilute. But we continue this review. And we ask that developers send MSDS sheets, literature studies. You know, in particular, the literature studies look at lower concentrations of some of these chemicals. MSDS largely looks at the undiluted forms and in many cases, the MSDS's are not appropriate for full hazard analysis.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Documentation requirements, Hazard assessment, Diagnostic test safety
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: What specific mitigation measures does the FDA recommend if a chemical in the test poses a potential but manageable safety risk?
CLARIFIED ANSWER: The FDA may recommend mitigation measures like wearing gloves or eye protection and implementing strong labeling if a chemical poses potential but manageable safety risks.
VERBATIM QUESTION: What specific mitigation measures does the FDA recommend if a chemical in the test poses a potential but manageable safety risk?
VERBATIM ANSWER: We look at, you know, if there is something that still remains in a range where it may not be entirely safe, we look at other mitigation, such as wearing gloves or eye protection. We prefer not to have to go that route. We also look at labeling, very strong labeling.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Mitigation measures for hazardous chemicals, Safety protocols in diagnostics
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: How are literature studies evaluated for determining the safety of chemicals at lower concentrations?
CLARIFIED ANSWER: FDA evaluates literature studies focusing on the safety of chemicals at lower concentrations, as MSDS reviews are often insufficient for hazard analysis.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We encourage developers to, you know, to submit documentation that says, you know, whether or not the chemicals that are in their test are hazardous, especially at the concentrations that are being used in the test. So a number of these reviews have happened. And we look at. And some of them have turned out to be safe to use without special considerations, mainly because they're fairly dilute. But we continue this review. And we ask that developers send MSDS sheets, literature studies. You know, in particular, the literature studies look at lower concentrations of some of these chemicals. MSDS largely looks at the undiluted forms and in many cases, the MSDS's are not appropriate for full hazard analysis.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: chemical safety, literature studies, toxicology review
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: What level of detail should be included in the submission of Material Safety Data Sheets (MSDS) for FDA review?
CLARIFIED ANSWER: The FDA asks developers to include MSDS sheets and literature studies highlighting whether chemicals in their tests are hazardous, especially at the concentrations used. MSDS sheets often focus on undiluted chemicals and may not suffice for full hazard analysis.
VERBATIM QUESTION: What level of detail should be included in the submission of Material Safety Data Sheets (MSDS) for FDA review?
VERBATIM ANSWER: We encourage developers to, you know, to submit documentation that says, you know, whether or not the chemicals that are in their test are hazardous, especially at the concentrations that are being used in the test. So a number of these reviews have happened. And we look at. And some of them have turned out to be safe to use without special considerations, mainly because they're fairly dilute. But we continue this review. And we ask that developers send MSDS sheets, literature studies. You know, in particular, the literature studies look at lower concentrations of some of these chemicals. MSDS largely looks at the undiluted forms and in many cases, the MSDS's are not appropriate for full hazard analysis.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: MSDS submission, Hazardous chemical review, Toxicology data
REVIEW FLAG: False

QA Block 2-9
CLARIFIED QUESTION: What labeling requirements or recommendations does the FDA suggest for tests containing potentially hazardous substances?
CLARIFIED ANSWER: The FDA conducts reviews of hazardous substances in test components, preferring non-toxic materials. If hazardous chemicals are unavoidable, the FDA evaluates their concentrations, requests supporting documentation like MSDS sheets and literature studies, and considers mitigation strategies like labeling and protective measures.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We have seen the use of hazardous chemicals in the development of certain tests. These typically fall into three different categories or uses. One is preservatives to prevent microbial growth in buffers. There are materials that are used to lyse cells or virus. And then there are materials to stabilize RNA. And as we began authorizing at-home tests and at-home collection devices, it became clear to us that this was an important review for the FDA to do. We would prefer that no hazardous materials enter the home. And if there are potential hazardous materials that they're of the type, that a dilute version of them as is the case in many examples, for example, detergents are usually in very low percent. It's only in high concentrations of detergent that, you know, say it splashes into the eye or could potentially cause harm to the patient. Others, some preservatives such that are being used, you know, are potentially hazardous substances. So we, in an effort to make testing as widely available, we know that developers sometimes cannot avoid some of these components. So we do a Hazardous Chemical Substance Toxicology Review. We encourage developers to, you know, to submit documentation that says, you know, whether or not the chemicals that are in their test are hazardous, especially at the concentrations that are being used in the test. So a number of these reviews have happened. And we look at. And some of them have turned out to be safe to use without special considerations, mainly because they're fairly dilute. But we continue this review. And we ask that developers send MSDS sheets, literature studies. You know, in particular, the literature studies look at lower concentrations of some of these chemicals. MSDS largely looks at the undiluted forms and in many cases, the MSDS's are not appropriate for full hazard analysis. We look at, you know, if there is something that still remains in a range where it may not be entirely safe, we look at other mitigation, such as wearing gloves or eye protection. We prefer not to have to go that route. We also look at labeling, very strong labeling. So, yes, we would prefer that non-toxic materials are used. We know that in the effort to get tests out there that it may not be possible to move away from them at this time. So we just look for mitigations. And we look at the available data to make the best decisions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Hazardous substances in tests, Labeling requirements, FDA evaluation process
REVIEW FLAG: False

QA Block 2-10
CLARIFIED QUESTION: Does the FDA provide any guidance or examples of chemicals that have been deemed safe at low concentrations?
CLARIFIED ANSWER: FDA encourages developers to submit documentation on the safety of chemicals in tests, especially at their concentrations. Reviews have determined that many chemicals are safe at dilute levels without special considerations.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We encourage developers to, you know, to submit documentation that says, you know, whether or not the chemicals that are in their test are hazardous, especially at the concentrations that are being used in the test. So a number of these reviews have happened. And we look at. And some of them have turned out to be safe to use without special considerations, mainly because they're fairly dilute.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Chemical safety, Toxicology review, Concentration limits
REVIEW FLAG: False


#### 3. Guidance on Antibody Testing After COVID-19 Vaccination

QA Block 3-1
CLARIFIED QUESTION: Will the FDA provide a template or guidance on an antibody level that demonstrates protection after vaccination to help healthcare providers track patient protection levels?
CLARIFIED ANSWER: FDA does not currently recommend antibody testing to assess immunity after COVID-19 vaccination. Further research is needed to determine the significance of antibody levels and their correlation with protection. FDA may consider validation approaches for antibody tests as science progresses.
VERBATIM QUESTION: Will the FDA provide a template or guidance on an antibody level that demonstrates protection after vaccination to help healthcare providers track patient protection levels?
VERBATIM ANSWER: We did note in our recent safety communication, titled the Antibody Testing, is not currently recommended to assess immunity after COVID-19 vaccination. And also this topic was discussed by the CDC that more research is needed to understand the meaning of a positive or negative antibody test beyond the presence or absence of antibodies, including in people who received a COVID-19 vaccination and people who have been exposed and have SARS-CoV-2 antibodies, and in people who are not fully vaccinated. As the science progresses in this area, we learn more about the potential correlation between the development of a specific level or concentration of antibodies and protection from infection, we'll consider the appropriate validation approaches for tests for use in monitoring such protection.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: antibody testing, FDA guidance, post-vaccination immunity
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What is the FDA's timeline for determining appropriate validation approaches for tests that monitor protection post-vaccination?
CLARIFIED ANSWER: The FDA will consider appropriate validation approaches for tests monitoring protection post-vaccination as more scientific understanding develops between antibody levels and immunity.
VERBATIM QUESTION: What is the FDA's timeline for determining appropriate validation approaches for tests that monitor protection post-vaccination?
VERBATIM ANSWER: As the science progresses in this area, we learn more about the potential correlation between the development of a specific level or concentration of antibodies and protection from infection, we'll consider the appropriate validation approaches for tests for use in monitoring such protection.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: antibody tests, post-vaccination immunity, validation approaches
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Will the FDA consider issuing specific recommendations for interpreting positive or negative antibody test results for partially vaccinated individuals?
CLARIFIED ANSWER: The FDA does not currently recommend using antibody tests to assess immunity after COVID-19 vaccination. More research is needed to interpret positive or negative antibody test results and their correlation with immunity, but future recommendations may be considered as science progresses.
VERBATIM QUESTION: Will the FDA consider issuing specific recommendations for interpreting positive or negative antibody test results for partially vaccinated individuals?
VERBATIM ANSWER: So we did note in our recent safety communication, titled the Antibody Testing, is not currently recommended to assess immunity after COVID-19 vaccination. And also this topic was discussed by the CDC that more research is needed to understand the meaning of a positive or negative antibody test beyond the presence or absence of antibodies, including in people who received a COVID-19 vaccination and people who have been exposed and have SARS-CoV-2 antibodies, and in people who are not fully vaccinated. As the science progresses in this area, we learn more about the potential correlation between the development of a specific level or concentration of antibodies and protection from infection, we'll consider the appropriate validation approaches for tests for use in monitoring such protection.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Antibody testing recommendations, Partially vaccinated individuals, COVID-19 immunity assessment
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: What kind of alternatives can the Review Team suggest if developers struggle to collect sufficient positive and negative specimens?
CLARIFIED ANSWER: Developers struggling to gather sufficient positive and negative specimens can contact the FDA Review Team to explore potential alternatives or suggestions.
VERBATIM QUESTION: What kind of alternatives can the Review Team suggest if developers struggle to collect sufficient positive and negative specimens?
VERBATIM ANSWER: If developers are having a hard time getting the positives and negatives they need, you know, they always have the opportunity to reach out to the Review Team for any alternatives that we might be able to suggest or that you suggest and would like to run by us.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Alternatives for specimen collection, FDA Review Team support
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: How should developers prioritize testing strategies while research on antibody correlations with protection is ongoing?
CLARIFIED ANSWER: The FDA does not currently recommend antibody testing to assess COVID-19 immunity. Research is ongoing to understand antibody level correlations with protection. Developers should contact the FDA Review Team for assistance with validation challenges.
VERBATIM QUESTION: How should developers prioritize testing strategies while research on antibody correlations with protection is ongoing?
VERBATIM ANSWER: So we did note in our recent safety communication, titled the Antibody Testing, is not currently recommended to assess immunity after COVID-19 vaccination. And also this topic was discussed by the CDC that more research is needed to understand the meaning of a positive or negative antibody test beyond the presence or absence of antibodies, including in people who received a COVID-19 vaccination and people who have been exposed and have SARS-CoV-2 antibodies, and in people who are not fully vaccinated. As the science progresses in this area, we learn more about the potential correlation between the development of a specific level or concentration of antibodies and protection from infection, we'll consider the appropriate validation approaches for tests for use in monitoring such protection. You know, for certain things. If developers are having a hard time getting the positives and negatives they need, you know, they always have the opportunity to reach out to the Review Team for any alternatives that we might be able to suggest or that you suggest and would like to run by us.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: antibody testing, test validation, developer guidance
REVIEW FLAG: False


#### 4. FDA Guidelines for COVID Test Validation and Sample Use

QA Block 4-1
CLARIFIED QUESTION: Would FDA consider reducing the sample sizes or requiring fewer samples for point of care COVID antibody test validations, given the challenges with dropping positivity rates and rising vaccination rates?
CLARIFIED ANSWER: Sponsors should attempt to collect the required positives through a prospective study. If unable, they should contact the FDA Review Team or use the mailbox for guidance on alternatives.
VERBATIM QUESTION: Would FDA consider reducing the sample sizes or requiring fewer samples for point of care COVID antibody test validations, given the challenges with dropping positivity rates and rising vaccination rates?
VERBATIM ANSWER: As Tim has said, previously as well, if sponsors - we do want sponsors to attempt get the requested positives through a prospective study. But if a sponsor is not able to do so, we would ask that they reach out to the Review Team or to the mailbox for additional input on alternatives.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: COVID antibody test validation, Sample size requirements, Prospective study alternative approaches
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: What are the pre-EUA review timelines, and where can information about them be found?
CLARIFIED ANSWER: The FDA reviews pre-EUA and EUA requests as quickly as possible, providing updates even if a submission is awaiting assignment. Additional questions can be directed to the relevant point of contact or the EUA email box. Further information is available in the FAQs section of the COVID-19 Test Development and Review page.
VERBATIM QUESTION: What are the pre-EUA review timelines, and where can information about them be found?
VERBATIM ANSWER: You know, as Tim noted, we do start to review both pre-EUA and EUA requests as quickly as we can. We do communicate with each sponsor regarding their submission as soon as possible and provide updates as much as we can, including while a submission might be sitting in queue waiting to be assigned to a reviewer. If you have additional questions, you can always send a follow-up email to the point of contact that has been corresponding with you or to the EUA email box. And we also do have some information on our FAQs in the COVID-19 Test Development and Review Section about timelines.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: pre-EUA review timelines, EUA communication, FAQ resources
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Does the FDA have a preference on the type of banked samples to use to supplement prospectively collected positive samples for molecular diagnostic tests, particularly for point of care tests?
CLARIFIED ANSWER: The FDA prefers samples, whether banked or fresh, to match the type intended for use with the device. For example, anterior nasal swabs should be used if anterior nasal swabs are claimed. Nasopharyngeal swabs, considered the most challenging matrix, can also serve as a comparator and may support claims for other upper respiratory specimen types.
VERBATIM QUESTION: Does the FDA have a preference on the type of banked samples to use to supplement prospectively collected positive samples for molecular diagnostic tests, particularly for point of care tests?
VERBATIM ANSWER: So generally, we do want to see samples, whether banked or fresh tested that match the sample type that you intend to claim for your device. So if you are looking to claim anterior nasal swabs, we would recommend generally using anterior nasal swabs for your study. Additionally, you know, we do - we have previously said that that nasopharyngeal is the preferred comparator and also that it is the most challenging upper respiratory matrix. And typically, if you do validate with nasopharyngeal, since we do consider that to be the most challenging provided there are no other concerns or issues, we would typically allow for a nasopharyngeal specimen to support an intended use also for nasal swabs and other upper respiratory specimen types.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: Banked samples for molecular diagnostics, FDA sample preference, Point of care tests
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: If pursuing a molecular diagnostic EUA for nasal swab samples, should sponsors test banked anterior nasal swabs, or would it be better to use banked nasopharyngeal swabs since nasopharyngeal swabs are considered the most challenging upper respiratory matrix?
CLARIFIED ANSWER: FDA recommends that sponsors use samples matching the type claimed for the device, such as anterior nasal swabs for anterior nasal swab claims. Nasopharyngeal swabs are preferred as a comparator since they are the most challenging matrix and can support intended use for other upper respiratory specimen types.
VERBATIM QUESTION: If pursuing a molecular diagnostic EUA for nasal swab samples, should sponsors test banked anterior nasal swabs, or would it be better to use banked nasopharyngeal swabs since nasopharyngeal swabs are considered the most challenging upper respiratory matrix?
VERBATIM ANSWER: So generally, we do want to see samples, whether banked or fresh tested that match the sample type that you intend to claim for your device. So if you are looking to claim anterior nasal swabs, we would recommend generally using anterior nasal swabs for your study. Additionally, you know, we do - we have previously said that that nasopharyngeal is the preferred comparator and also that it is the most challenging upper respiratory matrix. And typically, if you do validate with nasopharyngeal, since we do consider that to be the most challenging provided there are no other concerns or issues, we would typically allow for a nasopharyngeal specimen to support an intended use also for nasal swabs and other upper respiratory specimen types.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Toby Lowe (FDA IVD Assoc Director)
TOPICS: molecular diagnostic EUA, nasal swab validation, nasopharyngeal swabs
REVIEW FLAG: False


#### 5. Understanding Antibody Tests for Immunity and Vaccine Effectiveness

QA Block 5-1
CLARIFIED QUESTION: What is expected from the antibody test regarding information about immunity to a vaccine?
CLARIFIED ANSWER: The FDA agrees with CDC that serology tests should not be used for routine diagnosis. Regarding immunity testing, future advancements might help determine specific antibody levels or types that correlate with protection, such as preventing reinfection or severe outcomes. Vaccine studies are helpful for tracking immune responses over time to correlate with outcomes like illness prevention.
VERBATIM QUESTION: What is expected from the antibody test regarding information about immunity to a vaccine?
VERBATIM ANSWER: Yes. So first, to clarify the first point. Yes, the FDA agrees with what you represented from the CDC that the serology test should not be used for - routinely for diagnosis. There are some situations, of course, lingering infection where virus may be negative. And clinicians want to know, particularly in long COVID situations, and you want to know if they've ever been exposed. And clinicians can order those for their purposes. Regarding immunity and protection, of course, this isn't a diagnostic test. This isn't saying you are currently infected with SARS. What it's more designed to do, should we get there with this virus and there's every belief that we will get there. Our science will advance to the point where we understand what it means to be immune to SARS. That is, what level perhaps of antibody or what presence of different types of antibodies like neutralizing antibodies correlate with outcomes that's showing that folks with a certain level of antibody or type of antibody do not get re-infected or if they get infected, it's asymptomatic. So those just - those studies require close observation of patients. And oftentimes, you know, it might be the best study conditions to monitor patients who have received the different types of vaccines and then monitoring antibody production after the vaccines and the levels. You know, the obvious reason to use vaccine studies is that we know exactly when these patients have been vaccinated. So we know the time course of the immune response and antibody levels and we can track those over time and correlate them with outcomes. That is, do they avoid getting sick? Do they avoid hospitalization? Is death from COVID prevented? Those are the important questions to ask. And until we know the correlation or say, the quantitative level of antibodies with outcomes, we - it's really hard just, you know, to say what a given antibody response means.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antibody testing, immunity and vaccine correlation, serology and COVID-19
REVIEW FLAG: False

QA Block 5-2
CLARIFIED QUESTION: Do we have any tests for other infectious diseases that are approved by the FDA that work similarly?
CLARIFIED ANSWER: FDA has fully authorized serology tests for infectious diseases like rubella, measles, and mumps, which are quantitative tests that help determine immunity based on standards of correlative protection.
VERBATIM QUESTION: Do we have any tests for other infectious diseases that are approved by the FDA that work similarly?
VERBATIM ANSWER: Yes. We have fully authorized some such serology tests for a number of vaccines and authorized, you know, them in a way that these are usually quantitative tests that can help clinicians make the determination on whether a person has, you know, achieved and/or maintains immunity for them. So, let's see, it looks like rubella, measle, mumps are examples traceable to a standard that is established as a correlative protection.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA approved tests, Infectious diseases, Serology tests
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: What are the specific situations where serology tests can be used in long COVID cases?
CLARIFIED ANSWER: The FDA states that serology tests should not be used routinely for diagnosis. However, in situations like long COVID or lingering infections where the virus tests negative, clinicians may use serology tests to determine prior exposure.
VERBATIM QUESTION: What are the specific situations where serology tests can be used in long COVID cases?
VERBATIM ANSWER: Yes. So first, to clarify the first point. Yes, the FDA agrees with what you represented from the CDC that the serology test should not be used for - routinely for diagnosis. There are some situations, of course, lingering infection where virus may be negative. And clinicians want to know, particularly in long COVID situations, and you want to know if they've ever been exposed. And clinicians can order those for their purposes.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology tests, long COVID, diagnostic applications
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: What is the process to identify levels of antibodies that correlate with immunity to SARS-CoV-2?
CLARIFIED ANSWER: Identifying antibody levels that correlate with SARS-CoV-2 immunity involves monitoring vaccinated patients to track immune responses, observing antibody levels over time, and correlating these levels with outcomes such as illness prevention, hospitalization avoidance, or death reduction.
VERBATIM QUESTION: What is the process to identify levels of antibodies that correlate with immunity to SARS-CoV-2?
VERBATIM ANSWER: Our science will advance to the point where we understand what it means to be immune to SARS. That is, what level perhaps of antibody or what presence of different types of antibodies like neutralizing antibodies correlate with outcomes that's showing that folks with a certain level of antibody or type of antibody do not get re-infected or if they get infected, it's asymptomatic. So those just - those studies require close observation of patients. And oftentimes, you know, it might be the best study conditions to monitor patients who have received the different types of vaccines and then monitoring antibody production after the vaccines and the levels. You know, the obvious reason to use vaccine studies is that we know exactly when these patients have been vaccinated. So we know the time course of the immune response and antibody levels and we can track those over time and correlate them with outcomes. That is, do they avoid getting sick? Do they avoid hospitalization? Is death from COVID prevented? Those are the important questions to ask. And until we know the correlation or say, the quantitative level of antibodies with outcomes, we - it's really hard just, you know, to say what a given antibody response means.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: SARS-CoV-2 immunity, antibody testing, vaccine studies
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: How can vaccine studies contribute to understanding antibody response and immunity over time?
CLARIFIED ANSWER: Vaccine studies help understand antibody levels over time and their correlation with immunity, protection, and outcomes such as preventing illness, hospitalization, or death. Tracking vaccinated individuals provides insight into immune response timelines.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Yes. So first, to clarify the first point. Yes, the FDA agrees with what you represented from the CDC that the serology test should not be used for - routinely for diagnosis. There are some situations, of course, lingering infection where virus may be negative. And clinicians want to know, particularly in long COVID situations, and you want to know if they've ever been exposed. And clinicians can order those for their purposes. Regarding immunity and protection, of course, this isn't a diagnostic test. This isn't saying you are currently infected with SARS. What it's more designed to do, should we get there with this virus and there's every belief that we will get there. Our science will advance to the point where we understand what it means to be immune to SARS. That is, what level perhaps of antibody or what presence of different types of antibodies like neutralizing antibodies correlate with outcomes that's showing that folks with a certain level of antibody or type of antibody do not get re-infected or if they get infected, it's asymptomatic. So those just - those studies require close observation of patients. And oftentimes, you know, it might be the best study conditions to monitor patients who have received the different types of vaccines and then monitoring antibody production after the vaccines and the levels. You know, the obvious reason to use vaccine studies is that we know exactly when these patients have been vaccinated. So we know the time course of the immune response and antibody levels and we can track those over time and correlate them with outcomes. That is, do they avoid getting sick? Do they avoid hospitalization? Is death from COVID prevented? Those are the important questions to ask. And until we know the correlation or say, the quantitative level of antibodies with outcomes, we - it's really hard just, you know, to say what a given antibody response means.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antibody response, vaccine studies, immune protection
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: What additional data or studies are needed before serology tests can indicate reliable immunity to SARS-CoV-2?
CLARIFIED ANSWER: FDA states that studies are needed to determine correlations between antibody levels, types (like neutralizing antibodies), and clinical outcomes such as avoidance of reinfection, hospitalization, or death. This can best be studied in vaccine recipients where antibody production can be monitored over time.
VERBATIM QUESTION: What additional data or studies are needed before serology tests can indicate reliable immunity to SARS-CoV-2?
VERBATIM ANSWER: Regarding immunity and protection, of course, this isn't a diagnostic test. This isn't saying you are currently infected with SARS. What it's more designed to do, should we get there with this virus and there's every belief that we will get there. Our science will advance to the point where we understand what it means to be immune to SARS. That is, what level perhaps of antibody or what presence of different types of antibodies like neutralizing antibodies correlate with outcomes that's showing that folks with a certain level of antibody or type of antibody do not get re-infected or if they get infected, it's asymptomatic. So those just - those studies require close observation of patients. And oftentimes, you know, it might be the best study conditions to monitor patients who have received the different types of vaccines and then monitoring antibody production after the vaccines and the levels. You know, the obvious reason to use vaccine studies is that we know exactly when these patients have been vaccinated. So we know the time course of the immune response and antibody levels and we can track those over time and correlate them with outcomes. That is, do they avoid getting sick? Do they avoid hospitalization? Is death from COVID prevented? Those are the important questions to ask. And until we know the correlation or say, the quantitative level of antibodies with outcomes, we - it's really hard just, you know, to say what a given antibody response means.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology tests, immunity studies, antibody correlation
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: What would constitute a standardized correlative protection for SARS-CoV-2 similar to other vaccines?
CLARIFIED ANSWER: FDA needs to identify the correlative protection measurement for SARS-CoV-2. Once established, they will inform developers on its use.
VERBATIM QUESTION: What would constitute a standardized correlative protection for SARS-CoV-2 similar to other vaccines?
VERBATIM ANSWER: Well, really what we need to know is for SARS, can we find a correlative production? You know, what is that measurement? And once we know that, you can bet that the FDA, Toby, and I will do our best to get the word out about what that is and what developers can do with that information.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: correlative protection, SARS-CoV-2, vaccine immunity
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: What is the timeline for establishing such a correlative protection for SARS-CoV-2?
CLARIFIED ANSWER: The FDA plans to identify the correlative protection for SARS-CoV-2 and will disseminate the findings promptly once determined.
VERBATIM QUESTION: What is the timeline for establishing such a correlative protection for SARS-CoV-2?
VERBATIM ANSWER: Well, really what we need to know is for SARS, can we find a correlative production? You know, what is that measurement? And once we know that, you can bet that the FDA, Toby, and I will do our best to get the word out about what that is and what developers can do with that information.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: SARS-CoV-2 correlative protection, FDA communication of findings
REVIEW FLAG: False


#### 6. Connecting Digital Test Tools with Developers Through FDA

QA Block 6-1
CLARIFIED QUESTION: Can the FDA connect our startup to COVID-19 test developers who might need a service to capture and report rapid test data since we have a deployable product for this purpose?
CLARIFIED ANSWER: The FDA recommends emailing the EUA Templates address to contact Dr. Sara Brenner, who oversees COVID response and connectivity, to facilitate connections with relevant test developers.
VERBATIM QUESTION: Can the FDA connect our startup to COVID-19 test developers who might need a service to capture and report rapid test data since we have a deployable product for this purpose?
VERBATIM ANSWER: Well, yes, first of all, thanks for reaching out. If you send an email to our Templates email address, EUA Templates email address and contact - and ask to contact Dr. Sara, S-A-R-A, Brenner, B-R-E-N-N-E-R. Sara heads up that part of our COVID response and has been involved with the prior and current Administration on data and connectivity. So she would know exactly who, you know, she could put you and or anyone else in contact with the right people to make the connections. That could be helpful. So, yes, Dr. Sara Brenner. Just send an email and that will be forwarded to her. And she's really good.
SPEAKER QUESTION: Haromi Gardena
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: connecting startups with test developers, data reporting for COVID-19 tests
REVIEW FLAG: False

QA Block 6-2
CLARIFIED QUESTION: Who should we talk to in order to make our rapid test data capture and reporting service available to test developers?
CLARIFIED ANSWER: Email the FDA's EUA Templates address, requesting contact with Dr. Sara Brenner, who leads COVID data and connectivity efforts and can connect you with the relevant people.
VERBATIM QUESTION: Who should we talk to in order to make our rapid test data capture and reporting service available to test developers?
VERBATIM ANSWER: Well, yes, first of all, thanks for reaching out. If you send an email to our Templates email address, EUA Templates email address and contact - and ask to contact Dr. Sara, S-A-R-A, Brenner, B-R-E-N-N-E-R. Sara heads up that part of our COVID response and has been involved with the prior and current Administration on data and connectivity. So she would know exactly who, you know, she could put you and or anyone else in contact with the right people to make the connections. That could be helpful. So, yes, Dr. Sara Brenner. Just send an email and that will be forwarded to her. And she's really good.
SPEAKER QUESTION: Haromi Gardena
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: contacting FDA, rapid test reporting, EUA processes
REVIEW FLAG: False


#### 7. Harmonization of Low Viral Load Sample Guidelines

QA Block 7-1
CLARIFIED QUESTION: Does the FDA expect a similar distribution for retrospective influenza samples as it recommends for low viral load SARS-CoV-2 samples in the antigen template?
CLARIFIED ANSWER: The FDA expects 20%-25% low positive samples, defined as within 3 CTs of the LoD of the comparator assay, for influenza and other panel analytes in multi-analyte respiratory panels.
VERBATIM QUESTION: Does the FDA expect a similar distribution for retrospective influenza samples as it recommends for low viral load SARS-CoV-2 samples in the antigen template?
VERBATIM ANSWER: Great questions. So I want to clarify a little bit. We are in the process of harmonizing our recommendations across the board. That is for molecular and for antigen. So our antigen template may be updated in the future. But we are really looking at 20%, 20%- 25% of samples, plus or minus 3 CTs from the LoD of the comparator assay rather than what's in the current template. We've been providing that information to antigen sponsors. Toby, you can correct me if I'm wrong on any of those. We are also interested in seeing low positive for any of the other panel analytes. And CTs for those, you know, would be helpful in the evaluation of those and it would be the same sort of thing. We would like to see some, you know, 20%-25% percent low positives, plus or minus 3 CTs of the LoD of the flu or RSV or other panel members as well.
SPEAKER QUESTION: Kelly Turner
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA testing recommendations, Influenza sample distribution, Antigen template updates
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: How does the FDA characterize a low viral load influenza sample?
CLARIFIED ANSWER: The FDA defines low viral load influenza samples as those with CT values within 3 CTs of the limit of detection (LoD) of the comparator assay. They aim to include 20%-25% of such low-positive samples in evaluations.
VERBATIM QUESTION: How does the FDA characterize a low viral load influenza sample?
VERBATIM ANSWER: We are in the process of harmonizing our recommendations across the board. That is for molecular and for antigen. So our antigen template may be updated in the future. But we are really looking at 20%, 20%-25% of samples, plus or minus 3 CTs from the LoD of the comparator assay rather than what's in the current template. We've been providing that information to antigen sponsors. Toby, you can correct me if I'm wrong on any of those. We are also interested in seeing low positive for any of the other panel analytes. And CTs for those, you know, would be helpful in the evaluation of those and it would be the same sort of thing. We would like to see some, you know, 20%-25% percent low positives, plus or minus 3 CTs of the LoD of the flu or RSV or other panel members as well.
SPEAKER QUESTION: Kelly Turner
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: low viral load influenza samples, evaluation criteria, limit of detection (LoD)
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: What updates to the antigen template are currently being considered by the FDA?
CLARIFIED ANSWER: The FDA is considering updating the antigen template to align molecular and antigen recommendations and focusing on 20%-25% of samples within plus or minus 3 CTs from the LoD of the comparator assay.
VERBATIM QUESTION: What updates to the antigen template are currently being considered by the FDA?
VERBATIM ANSWER: We are in the process of harmonizing our recommendations across the board. That is for molecular and for antigen. So our antigen template may be updated in the future. But we are really looking at 20%, 20%- 25% of samples, plus or minus 3 CTs from the LoD of the comparator assay rather than what's in the current template. We've been providing that information to antigen sponsors.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen template updates, Sample distribution requirements
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: How should antigen test developers incorporate the recommendation for 20%-25% of samples being low positives within 3 CTs of the comparator assay's LoD?
CLARIFIED ANSWER: FDA recommends that 20%-25% of samples for antigen tests should be low positives within 3 CTs of the comparator assay's LoD. These guidelines may result in future updates to the antigen template.
VERBATIM QUESTION: How should antigen test developers incorporate the recommendation for 20%-25% of samples being low positives within 3 CTs of the comparator assay's LoD?
VERBATIM ANSWER: We are in the process of harmonizing our recommendations across the board. That is for molecular and for antigen. So our antigen template may be updated in the future. But we are really looking at 20%, 20%- 25% of samples, plus or minus 3 CTs from the LoD of the comparator assay rather than what's in the current template. We've been providing that information to antigen sponsors.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test guidelines, sample distribution, low positive criteria
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: What are the expectations for evaluating low positives for other analytes, such as RSV, in multi-analyte respiratory panels?
CLARIFIED ANSWER: FDA expects 20%-25% of low positive samples, defined as within 3 CTs of the assay's LoD, for all analytes in multi-analyte respiratory panels, including flu and RSV.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We are really looking at 20%-25% of samples, plus or minus 3 CTs from the LoD of the comparator assay rather than what's in the current template. We are also interested in seeing low positive for any of the other panel analytes. And CTs for those, you know, would be helpful in the evaluation of those and it would be the same sort of thing. We would like to see some, you know, 20%-25% percent low positives, plus or minus 3 CTs of the LoD of the flu or RSV or other panel members as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: multi-analyte respiratory panels, low positive sample evaluation, flu and RSV diagnostics
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: Are CT values for low positives in non-SARS-CoV-2 analytes like flu and RSV required to follow the same guidance as SARS-CoV-2?
CLARIFIED ANSWER: The FDA requires a similar methodology for non-SARS-CoV-2 analytes like flu and RSV, expecting 20%-25% low positives, within 3 CTs of the LoD for evaluation.
VERBATIM QUESTION: Are CT values for low positives in non-SARS-CoV-2 analytes like flu and RSV required to follow the same guidance as SARS-CoV-2?
VERBATIM ANSWER: We are also interested in seeing low positive for any of the other panel analytes. And CTs for those, you know, would be helpful in the evaluation of those and it would be the same sort of thing. We would like to see some, you know, 20%-25% percent low positives, plus or minus 3 CTs of the LoD of the flu or RSV or other panel members as well.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CT values, Low positives, Flu/RSV diagnostics
REVIEW FLAG: False


#### 8. Addressing Concerns in Antigen Test Review Process

QA Block 8-1
CLARIFIED QUESTION: What should we do if we receive irrelevant or accusatory questions from the reviewer during the antigen test review process?
CLARIFIED ANSWER: If you encounter irrelevant or accusatory questions during the antigen test review process, email the Templates email box with details of your submission (EUA number, name), and request to forward it to FDA directors Toby Lowe and Tim Stenzel for further review.
VERBATIM QUESTION: What should we do if we receive irrelevant or accusatory questions from the reviewer during the antigen test review process?
VERBATIM ANSWER: I'm always available. I am quite busy, unfortunately. But in this case, do send an email to the Templates email box with some details on your submission. The EUA number, the name. And ask for that to be forwarded to Toby and myself. Toby Lowe and Tim Stenzel. And we'll look into it and make sure that you get some communication back.
SPEAKER QUESTION: Christopher Patterson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test review process, communication with reviewer, FDA escalation procedures
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: Who should we contact if the assigned reviewer does not respond to our follow-up questions about missing data?
CLARIFIED ANSWER: If the assigned reviewer does not respond, email the Templates mailbox with submission details like the EUA number and name, and ask for it to be forwarded to FDA representatives Toby Lowe and Tim Stenzel to ensure communication.
VERBATIM QUESTION: Who should we contact if the assigned reviewer does not respond to our follow-up questions about missing data?
VERBATIM ANSWER: I'm always available. I am quite busy, unfortunately. But in this case, do send an email to the Templates email box with some details on your submission. The EUA number, the name. And ask for that to be forwarded to Toby and myself. Toby Lowe and Tim Stenzel. And we'll look into it and make sure that you get some communication back.
SPEAKER QUESTION: Christopher Patterson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission issues, FDA follow-up, communication
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: What details should be included in the email to the Templates email box regarding a submission issue?
CLARIFIED ANSWER: Include the EUA number and name, and request the email be forwarded to FDA representatives Toby Lowe and Tim Stenzel.
VERBATIM QUESTION: What details should be included in the email to the Templates email box regarding a submission issue?
VERBATIM ANSWER: The EUA number, the name. And ask for that to be forwarded to Toby and myself.
SPEAKER QUESTION: Christopher Patterson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission details, Templates email box, EUA communication
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: How can we ensure that submission issues are escalated appropriately within the FDA?
CLARIFIED ANSWER: Submission issues can be escalated by emailing the Templates email box with details such as the EUA number and name, asking for them to be forwarded to FDA representatives who will ensure communication is addressed.
VERBATIM QUESTION: How can we ensure that submission issues are escalated appropriately within the FDA?
VERBATIM ANSWER: I'm always available. I am quite busy, unfortunately. But in this case, do send an email to the Templates email box with some details on your submission. The EUA number, the name. And ask for that to be forwarded to Toby and myself. Toby Lowe and Tim Stenzel. And we'll look into it and make sure that you get some communication back.
SPEAKER QUESTION: Christopher Patterson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission escalation, communication with FDA
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Is it acceptable to directly address submission concerns to Dr. Stenzel or specific FDA representatives?
CLARIFIED ANSWER: FDA recommends emailing the Templates inbox with details, including EUA number and name, and requesting it be forwarded to appropriate representatives like FDA leadership (e.g., Dr. Stenzel).
VERBATIM QUESTION: Is it acceptable to directly address submission concerns to Dr. Stenzel or specific FDA representatives?
VERBATIM ANSWER: I'm always available. I am quite busy, unfortunately. But in this case, do send an email to the Templates email box with some details on your submission. The EUA number, the name. And ask for that to be forwarded to Toby and myself. Toby Lowe and Tim Stenzel. And we'll look into it and make sure that you get some communication back.
SPEAKER QUESTION: Christopher Patterson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Submission issues, Contacting FDA, Follow-up communication
REVIEW FLAG: False

QA Block 8-6
CLARIFIED QUESTION: What steps can a test developer take if they don't receive a response from their assigned reviewer?
CLARIFIED ANSWER: If a test developer does not receive a response from their assigned reviewer, they should email the Templates inbox with their EUA number and submission details, requesting it be forwarded to FDA leadership for review.
VERBATIM QUESTION: What steps can a test developer take if they don't receive a response from their assigned reviewer?
VERBATIM ANSWER: I'm always available. I am quite busy, unfortunately. But in this case, do send an email to the Templates email box with some details on your submission. The EUA number, the name. And ask for that to be forwarded to Toby and myself. Toby Lowe and Tim Stenzel. And we'll look into it and make sure that you get some communication back.
SPEAKER QUESTION: Christopher Patterson
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA review delays, follow-up processes
REVIEW FLAG: False


#### 9. Review Standards and Prioritization of Backlogged Applications

QA Block 9-1
CLARIFIED QUESTION: Do you have enough personnel to do the review?
CLARIFIED ANSWER: FDA has reassigned lower priority applications to support staff while higher priority ones were completed. Review processes and standards remain consistent, with complete reviews made when a reviewer is assigned.
VERBATIM QUESTION: Do you have enough personnel to do the review?
VERBATIM ANSWER: So there were definitely some lower priority applications that were put on pause and were assigned to some of our support staff to communicate with developers. As our reviewers have completed the work on the higher priority applications, there has been an opportunity to go back to some of the lower priority applications. The standards are still the same. The priorities are still the same. It's just as we've been able to work through the backlog, we are working in some cases into lower priority submissions now. Now many of these were able to be marketed through the notification pathways. And since that pathway was open to them and they were deemed to be a lower priority, that's why they were paused. But we're going back to them now. There really is no different standard. We, you know, we do - when the applications come in, we do a quick assessment. And we look and see what it is in order to prioritize it. Then we also look at whether there are any obvious concerns about the application. But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: review personnel, application prioritization, review standards
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: Is the review process different from when applications were reviewed last year compared to when they are being reviewed now?
CLARIFIED ANSWER: The review standards and priorities have remained consistent from last year to now. Lower-priority applications were paused and are now being reviewed as higher-priority applications are completed, but the same standards are applied.
VERBATIM QUESTION: Is the review process different from when applications were reviewed last year compared to when they are being reviewed now?
VERBATIM ANSWER: So there were definitely some lower priority applications that were put on pause and were assigned to some of our support staff to communicate with developers. As our reviewers have completed the work on the higher priority applications, there has been an opportunity to go back to some of the lower priority applications. The standards are still the same. The priorities are still the same. It's just as we've been able to work through the backlog, we are working in some cases into lower priority submissions now. Now many of these were able to be marketed through the notification pathways. And since that pathway was open to them and they were deemed to be a lower priority, that's why they were paused. But we're going back to them now. There really is no different standard. We, you know, we do - when the applications come in, we do a quick assessment. And we look and see what it is in order to prioritize it. Then we also look at whether there are any obvious concerns about the application. But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: review process, application prioritization, FDA standards
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: Are low priority applications being reviewed with a different standard than applications considered high priority last year?
CLARIFIED ANSWER: Lower priority applications are being reviewed now as backlog clears, but the standards and priorities remain the same as for higher priority applications.
VERBATIM QUESTION: Are low priority applications being reviewed with a different standard than applications considered high priority last year?
VERBATIM ANSWER: So there were definitely some lower priority applications that were put on pause and were assigned to some of our support staff to communicate with developers. As our reviewers have completed the work on the higher priority applications, there has been an opportunity to go back to some of the lower priority applications. The standards are still the same. The priorities are still the same. It's just as we've been able to work through the backlog, we are working in some cases into lower priority submissions now. Now many of these were able to be marketed through the notification pathways. And since that pathway was open to them and they were deemed to be a lower priority, that's why they were paused. But we're going back to them now. There really is no different standard. We, you know, we do - when the applications come in, we do a quick assessment. And we look and see what it is in order to prioritize it. Then we also look at whether there are any obvious concerns about the application. But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: priority applications, review standards, application backlog
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: Is the review process consistent compared to what was done previously?
CLARIFIED ANSWER: The review process has remained consistent, with the same standards and priorities applied. Lower priority applications were delayed but are now being reviewed with the same rigor as high-priority ones when assigned a reviewer.
VERBATIM QUESTION: Is the review process consistent compared to what was done previously?
VERBATIM ANSWER: The standards are still the same. The priorities are still the same. It's just as we've been able to work through the backlog, we are working in some cases into lower priority submissions now. Now many of these were able to be marketed through the notification pathways. And since that pathway was open to them and they were deemed to be a lower priority, that's why they were paused. But we're going back to them now. There really is no different standard. We, you know, we do - when the applications come in, we do a quick assessment. And we look and see what it is in order to prioritize it. Then we also look at whether there are any obvious concerns about the application. But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: review process consistency, low vs high priority applications
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: What are the criteria used to reprioritize paused, lower-priority COVID-19 test applications?
CLARIFIED ANSWER: Lower-priority applications paused earlier were reprioritized as higher-priority ones were reviewed. Prioritization involves a quick assessment including any obvious concerns, but full reviews occur only once assigned to a reviewer.
VERBATIM QUESTION: What are the criteria used to reprioritize paused, lower-priority COVID-19 test applications?
VERBATIM ANSWER: There were definitely some lower priority applications that were put on pause and were assigned to some of our support staff to communicate with developers. As our reviewers have completed the work on the higher priority applications, there has been an opportunity to go back to some of the lower priority applications. The standards are still the same. The priorities are still the same. It's just as we've been able to work through the backlog, we are working in some cases into lower priority submissions now. Now many of these were able to be marketed through the notification pathways. And since that pathway was open to them and they were deemed to be a lower priority, that's why they were paused. But we're going back to them now. There really is no different standard. We do - when the applications come in, we do a quick assessment. And we look and see what it is in order to prioritize it. Then we also look at whether there are any obvious concerns about the application. But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Application prioritization, Review standards, Backlog management
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: What is the process for assigning paused applications to reviewers once backlog issues are alleviated?
CLARIFIED ANSWER: Paused lower-priority applications are assigned to support staff initially, but as higher-priority reviews are completed, these are reassigned to reviewers. Initial quick assessments are done for prioritization, with a complete review occurring when formally assigned.
VERBATIM QUESTION: What is the process for assigning paused applications to reviewers once backlog issues are alleviated?
VERBATIM ANSWER: There were definitely some lower priority applications that were put on pause and were assigned to some of our support staff to communicate with developers. As our reviewers have completed the work on the higher priority applications, there has been an opportunity to go back to some of the lower priority applications. The standards are still the same. The priorities are still the same. It's just as we've been able to work through the backlog, we are working in some cases into lower priority submissions now. Now many of these were able to be marketed through the notification pathways. And since that pathway was open to them and they were deemed to be a lower priority, that's why they were paused. But we're going back to them now. There really is no different standard. We, you know, we do - when the applications come in, we do a quick assessment. And we look and see what it is in order to prioritize it. Then we also look at whether there are any obvious concerns about the application. But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: review process for paused applications, prioritization of applications, FDA review standards
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: Do lower priority applications that were initially marketed through notification pathways require a secondary full review when revisited?
CLARIFIED ANSWER: Lower priority applications marketed through notification pathways undergo a full review when revisited. The standards remain the same, and review occurs only after their reassignment.
VERBATIM QUESTION: Do lower priority applications that were initially marketed through notification pathways require a secondary full review when revisited?
VERBATIM ANSWER: Now many of these were able to be marketed through the notification pathways. And since that pathway was open to them and they were deemed to be a lower priority, that's why they were paused. But we're going back to them now. There really is no different standard. We, you know, we do - when the applications come in, we do a quick assessment. And we look and see what it is in order to prioritize it. Then we also look at whether there are any obvious concerns about the application. But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: Kaumudi Venkat
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: review standards, low priority applications, notification pathway
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: What is the scope of the quick assessment process conducted when applications are first received?
CLARIFIED ANSWER: FDA performs a quick assessment of applications upon submission to prioritize them and identify any obvious concerns but does not conduct a complete review until a reviewer is assigned.
VERBATIM QUESTION: What is the scope of the quick assessment process conducted when applications are first received?
VERBATIM ANSWER: We, you know, we do - when the applications come in, we do a quick assessment. And we look and see what it is in order to prioritize it. Then we also look at whether there are any obvious concerns about the application. But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: application assessment, prioritization of reviews
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: How are concerns identified during the quick assessment addressed before assigning an application to a reviewer?
CLARIFIED ANSWER: FDA performs a quick assessment of applications to prioritize them and identify obvious concerns, but a complete review is only done once assigned to a reviewer, who addresses any issues by contacting the developer.
VERBATIM QUESTION: How are concerns identified during the quick assessment addressed before assigning an application to a reviewer?
VERBATIM ANSWER: We, you know, we do - when the applications come in, we do a quick assessment. And we look and see what it is in order to prioritize it. Then we also look at whether there are any obvious concerns about the application. But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: application assessment, prioritization process, developer communication
REVIEW FLAG: False

QA Block 9-10
CLARIFIED QUESTION: What specific communication should developers expect from reviewers when issues arise during the complete review phase?
CLARIFIED ANSWER: FDA stated that during the complete review phase, if issues are found, reviewers will contact developers and clearly communicate these issues.
VERBATIM QUESTION: What specific communication should developers expect from reviewers when issues arise during the complete review phase?
VERBATIM ANSWER: But we are not doing a complete review of those applications until it is assigned to a reviewer. And at that point, they do a complete review. And if there are issues, they will reach out to the developer and state those issues clearly.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: communication with developers, review process, issue resolution
REVIEW FLAG: False


#### 10. Evolving Antigen Testing Requirements for Flu and COVID Tests

QA Block 10-1
CLARIFIED QUESTION: What is the requirement for achieving a certain percentage of low positive samples in flu testing under the FDA guidance?
CLARIFIED ANSWER: The FDA has flexibility regarding the requirement for low positive flu samples due to limited flu circulation. Banked samples can be used, and post-market commitments may be possible. Submissions are still encouraged even if low positive targets are difficult to meet.
VERBATIM QUESTION: What is the requirement for achieving a certain percentage of low positive samples in flu testing under the FDA guidance?
VERBATIM ANSWER: And so yes, our thinking sometimes evolves here. And this just reflects an ongoing evolution. And we - you know, in the case of panel tests that we've not reviewed before for EUA, we do have flexibility. So, for example, banked samples can be used for - you know, and we know that there's very little flu circulating right now. And so we've made good use of bank samples. And those bank samples may not - they may not have, you know, a good distribution, say, of positivity and that's something that we had hoped to see. So but, so we haven't in prior situations asked about that. So but we do have the flexibility to put in some commitments post-market. So I would not - if you're struggling to get those low positives for non-SARS targets, I would still submit and work with our team.
SPEAKER QUESTION: Rhina Vemon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Low positive flu sample requirement, FDA review flexibility, Post-market commitments
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Does the requirement for a percentage of low positive samples apply to molecular point of care tests?
CLARIFIED ANSWER: For molecular point of care tests, the FDA acknowledges evolving flexibility due to challenges in acquiring low positive flu samples. Banked samples and post-market commitments may suffice; submitters should work with the FDA.
VERBATIM QUESTION: Does the requirement for a percentage of low positive samples apply to molecular point of care tests?
VERBATIM ANSWER: And so yes, our thinking sometimes evolves here. And this just reflects an ongoing evolution. And we - you know, in the case of panel tests that we've not reviewed before for EUA, we do have flexibility. So, for example, banked samples can be used for - you know, and we know that there's very little flu circulating right now. And so we've made good use of bank samples. And those bank samples may not - they may not have, you know, a good distribution, say, of positivity and that's something that we had hoped to see. So but, so we haven't in prior situations asked about that. So but we do have the flexibility to put in some commitments post-market. So I would not - if you're struggling to get those low positives for non-SARS targets, I would still submit and work with our team.
SPEAKER QUESTION: Rhina Vemon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: low positive sample requirements, molecular point of care tests, FDA flexibility
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Can banked flu samples with potentially limited positivity distribution be used to meet FDA submission requirements for flu A/B and COVID-19 tests?
CLARIFIED ANSWER: The FDA allows the use of banked flu samples for EUA submissions even if they lack a good positivity distribution, acknowledging this as a flexible approach due to limited circulating flu. Post-market commitments may also address this.
VERBATIM QUESTION: Can banked flu samples with potentially limited positivity distribution be used to meet FDA submission requirements for flu A/B and COVID-19 tests?
VERBATIM ANSWER: And so yes, our thinking sometimes evolves here. And this just reflects an ongoing evolution. And we - you know, in the case of panel tests that we've not reviewed before for EUA, we do have flexibility. So, for example, banked samples can be used for - you know, and we know that there's very little flu circulating right now. And so we've made good use of bank samples. And those bank samples may not - they may not have, you know, a good distribution, say, of positivity and that's something that we had hoped to see. So but, so we haven't in prior situations asked about that. So but we do have the flexibility to put in some commitments post-market. So I would not - if you're struggling to get those low positives for non-SARS targets, I would still submit and work with our team.
SPEAKER QUESTION: Rhina Vemon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: banked flu samples, EUA submissions, positivity distribution
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: What level of flexibility does the FDA have when evaluating new panel tests under EUA?
CLARIFIED ANSWER: FDA has flexibility when evaluating new panel tests under EUA, allowing the use of banked samples and post-market commitments, especially when certain sample types like low positives are difficult to obtain.
VERBATIM QUESTION: What level of flexibility does the FDA have when evaluating new panel tests under EUA?
VERBATIM ANSWER: And so yes, our thinking sometimes evolves here. And this just reflects an ongoing evolution. And we - you know, in the case of panel tests that we've not reviewed before for EUA, we do have flexibility. So, for example, banked samples can be used for - you know, and we know that there's very little flu circulating right now. And so we've made good use of bank samples. And those bank samples may not - they may not have, you know, a good distribution, say, of positivity and that's something that we had hoped to see. So but, so we haven't in prior situations asked about that. So but we do have the flexibility to put in some commitments post-market. So I would not - if you're struggling to get those low positives for non-SARS targets, I would still submit and work with our team.
SPEAKER QUESTION: Rhina Vemon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: flexibility in EUA evaluations, use of banked samples, post-market commitments
REVIEW FLAG: False

QA Block 10-6
CLARIFIED QUESTION: Can banked samples with uneven positivity distributions still be used in EUA submissions during times of low clinical sample availability?
CLARIFIED ANSWER: Yes, FDA allows the use of banked samples with uneven positivity distributions for EUA submissions when clinical samples are scarce, and they may include post-market commitments.
VERBATIM QUESTION: Can banked samples with uneven positivity distributions still be used in EUA submissions during times of low clinical sample availability?
VERBATIM ANSWER: And so yes, our thinking sometimes evolves here. And this just reflects an ongoing evolution. And we - you know, in the case of panel tests that we've not reviewed before for EUA, we do have flexibility. So, for example, banked samples can be used for - you know, and we know that there's very little flu circulating right now. And so we've made good use of bank samples. And those bank samples may not - they may not have, you know, a good distribution, say, of positivity and that's something that we had hoped to see. So but, so we haven't in prior situations asked about that. So but we do have the flexibility to put in some commitments post-market. So I would not - if you're struggling to get those low positives for non-SARS targets, I would still submit and work with our team.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Banked samples, EUA submission, Low sample availability
REVIEW FLAG: False

QA Block 10-7
CLARIFIED QUESTION: Will the FDA make post-market commitments to address the requirement for low positive samples in cases where they are not available during pre-submission?
CLARIFIED ANSWER: FDA has the flexibility to make post-market commitments if low positive samples are unavailable during pre-submission, and applicants should still submit and collaborate with the FDA team.
VERBATIM QUESTION: Will the FDA make post-market commitments to address the requirement for low positive samples in cases where they are not available during pre-submission?
VERBATIM ANSWER: So but, so we haven't in prior situations asked about that. So but we do have the flexibility to put in some commitments post-market. So I would not - if you're struggling to get those low positives for non-SARS targets, I would still submit and work with our team.
SPEAKER QUESTION: Rhina Vemon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: post-market commitments, low positive samples, submission flexibility
REVIEW FLAG: False

QA Block 10-8
CLARIFIED QUESTION: Is the low positive requirement applicable to non-SARS targets in panel tests for EUA?
CLARIFIED ANSWER: The FDA acknowledges evolving requirements and has flexibility for panel tests under EUA, including using banked samples when low flu circulation limits positivity data. The FDA advises submitting and collaborating on non-SARS targets, even without complete low-positive data.
VERBATIM QUESTION: Is the low positive requirement applicable to non-SARS targets in panel tests for EUA?
VERBATIM ANSWER: And so yes, our thinking sometimes evolves here. And this just reflects an ongoing evolution. And we - you know, in the case of panel tests that we've not reviewed before for EUA, we do have flexibility. So, for example, banked samples can be used for - you know, and we know that there's very little flu circulating right now. And so we've made good use of bank samples. And those bank samples may not - they may not have, you know, a good distribution, say, of positivity and that's something that we had hoped to see. So but, so we haven't in prior situations asked about that. So but we do have the flexibility to put in some commitments post-market. So I would not - if you're struggling to get those low positives for non-SARS targets, I would still submit and work with our team.
SPEAKER QUESTION: Rhina Vemon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: low positive requirement, non-SARS targets, EUA flexibility
REVIEW FLAG: False


#### 11. Antibody Titer, Immunity, and CDC Guidelines Clarification

QA Block 11-1
CLARIFIED QUESTION: Can you expand on the apparent contradiction between CDC's guidelines on vaccinated individuals not needing masks and the lack of correlation between antibody titer and immunity?
CLARIFIED ANSWER: The FDA has not seen clinical data supporting immunity or protection claims and focuses on test authorizations, while the CDC is responsible for issuing guidance in this area.
VERBATIM QUESTION: Can you expand on the apparent contradiction between CDC's guidelines on vaccinated individuals not needing masks and the lack of correlation between antibody titer and immunity?
VERBATIM ANSWER: Yes. So we're - you know, at the FDA we're looking at, you know, what uses and claims for a test can be supported by data. And what we're saying is we don't - we haven't yet seen the clinical data that supports immunity or protection claims. And, you know, and I'm aware of CDC guidelines in these areas. But, you know, they're the experts on their guidelines. And, you know, we focus on what we can authorize for tests and the meaning of that. So, you know, our missions are a little bit different. They - I mean, and I leave it to them to, you know, expound on their guidances.
SPEAKER QUESTION: Robert de Tullio
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: CDC guidelines, antibody titer, FDA test authorization
REVIEW FLAG: False


#### 12. FDA Reference Panel and Inclusivity for Testing

QA Block 12-1
CLARIFIED QUESTION: Is the FDA reference panel required only for molecular tests or is there also a panel for antigen tests?
CLARIFIED ANSWER: The FDA does not have a reference panel for antigen tests, only for molecular tests, due to the challenges in producing a universal panel for antigens.
VERBATIM QUESTION: Is the FDA reference panel required only for molecular tests or is there also a panel for antigen tests?
VERBATIM ANSWER: So for - first of all, for the Reference Panel, so we do not have a Reference Panel for antigen test. We have one for molecular. And there were various reasons for that, largely because producing something that will work uniformly for antigen test is a little bit more difficult. And, you know, so there are thoughts about what we need to do there.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA reference panel, Molecular vs. antigen tests
REVIEW FLAG: False

QA Block 12-2
CLARIFIED QUESTION: Is the inclusivity analytical sensitivity performance study required only for molecular tests?
CLARIFIED ANSWER: Inclusivity analytical sensitivity studies are primarily done for molecular tests using in silico methods. However, FDA expects antigen test developers to monitor potential impacts of mutations and test those impacts using wet lab methods instead of in silico analysis.
VERBATIM QUESTION: Is the inclusivity analytical sensitivity performance study required only for molecular tests?
VERBATIM ANSWER: As far as inclusivity goes so, you know, we largely have relied on in silico inclusivity testing for molecular tests. And that's fairly straightforward for molecular tests because, you know, you have primers and your probes and you can do homology analysis to the known mutations and variants out there and detect if there's anything of significance that would lead to a false negative. That sort of in silico analysis is at best very challenging for antigen tests. You know, we are asking all developers, serology, antigen, and molecular to - through guidance that we issued on this to be monitoring indications and determine whether - when a situation exists where there may be an impact and they need to do more work. And more work can involve getting a hold of through various means and be able to test for mutations and variants that might impact the test performance. For developers who are still developing their tests, we ask them to do the same thing. And antigen tests would fall into that category. So antigen tests should know, you know, which antigen was used to generate their antibody or antibodies and epitope mapping information as well for those antibodies so that they can look at the sequence data. Translate it to amino acid and see were there are any potential impacts. And if there are potential impacts, there are various ways to test in vitro the impact of those mutations on antigen tests. And we would ask the developers for those mutations or variants that may impact their test to be able to do that testing. That would be wet testing, rather than in silico testing.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Inclusivity sensitivity study, Molecular vs antigen tests, Test performance monitoring
REVIEW FLAG: False

QA Block 12-3
CLARIFIED QUESTION: What challenges prevent the FDA from producing a reference panel for antigen tests?
CLARIFIED ANSWER: The FDA does not have a reference panel for antigen tests because producing something that will work uniformly is more challenging. Efforts are ongoing to monitor the molecular impact of mutations and variants.
VERBATIM QUESTION: What challenges prevent the FDA from producing a reference panel for antigen tests?
VERBATIM ANSWER: We do not have a Reference Panel for antigen test. We have one for molecular. And there were various reasons for that, largely because producing something that will work uniformly for antigen test is a little bit more difficult. And, you know, so there are thoughts about what we need to do there. For antigen test, though, we are carefully monitoring as the molecular impact of mutations and variants. And so we'll continue those efforts.
SPEAKER QUESTION: Dana Hummel
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Reference panel challenges, Antigen tests, FDA monitoring efforts
REVIEW FLAG: False

QA Block 12-4
CLARIFIED QUESTION: Why is in silico inclusivity testing challenging for antigen tests?
CLARIFIED ANSWER: In silico inclusivity testing is challenging for antigen tests because they lack primers or probes for homology analysis like molecular tests. Developers must rely on wet testing and epitope mapping to address potential impacts of mutations or variants.
VERBATIM QUESTION: Why is in silico inclusivity testing challenging for antigen tests?
VERBATIM ANSWER: That sort of in silico analysis is at best very challenging for antigen tests. You know, we are asking all developers, serology, antigen, and molecular to - through guidance that we issued on this to be monitoring indications and determine whether - when a situation exists where there may be an impact and they need to do more work. And more work can involve getting a hold of through various means and be able to test for mutations and variants that might impact the test performance. For developers who are still developing their tests, we ask them to do the same thing. And antigen tests would fall into that category. So antigen tests should know, you know, which antigen was used to generate their antibody or antibodies and epitope mapping information as well for those antibodies so that they can look at the sequence data. Translate it to amino acid and see were there are any potential impacts. And if there are potential impacts, there are various ways to test in vitro the impact of those mutations on antigen tests. And we would ask the developers for those mutations or variants that may impact their test to be able to do that testing. That would be wet testing, rather than in silico testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: in silico inclusivity testing, antigen tests, mutations or variants
REVIEW FLAG: False

QA Block 12-5
CLARIFIED QUESTION: What specific steps should developers take to monitor variants and mutations impacting test performance?
CLARIFIED ANSWER: FDA advises developers to monitor mutations and variants, assess potential impacts, and conduct necessary testing to evaluate performance. Developers must understand the antigens used, perform epitope mapping, translate sequences, and test impacts through wet testing.
VERBATIM QUESTION: What specific steps should developers take to monitor variants and mutations impacting test performance?
VERBATIM ANSWER: You know, we are asking all developers, serology, antigen, and molecular to - through guidance that we issued on this to be monitoring indications and determine whether - when a situation exists where there may be an impact and they need to do more work. And more work can involve getting a hold of through various means and be able to test for mutations and variants that might impact the test performance. For developers who are still developing their tests, we ask them to do the same thing. And antigen tests would fall into that category. So antigen tests should know, you know, which antigen was used to generate their antibody or antibodies and epitope mapping information as well for those antibodies so that they can look at the sequence data. Translate it to amino acid and see were there are any potential impacts. And if there are potential impacts, there are various ways to test in vitro the impact of those mutations on antigen tests. And we would ask the developers for those mutations or variants that may impact their test to be able to do that testing. That would be wet testing, rather than in silico testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Monitoring variants, Test performance, Developer responsibilities
REVIEW FLAG: False

QA Block 12-6
CLARIFIED QUESTION: What information about antigens and antibodies is necessary for antigen test developers?
CLARIFIED ANSWER: Antigen test developers need to know which antigen was used to generate their antibodies, the epitope mapping information for those antibodies, and analyze sequence data for potential impacts. If impacts are identified, they should test the effects of mutations or variants in vitro through wet testing.
VERBATIM QUESTION: What information about antigens and antibodies is necessary for antigen test developers?
VERBATIM ANSWER: Antigen tests should know, you know, which antigen was used to generate their antibody or antibodies and epitope mapping information as well for those antibodies so that they can look at the sequence data. Translate it to amino acid and see were there are any potential impacts. And if there are potential impacts, there are various ways to test in vitro the impact of those mutations on antigen tests. And we would ask the developers for those mutations or variants that may impact their test to be able to do that testing. That would be wet testing, rather than in silico testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test requirements, antibodies and epitope mapping, test impact evaluation
REVIEW FLAG: False

QA Block 12-7
CLARIFIED QUESTION: How can antigen test developers conduct in vitro testing for potential impacts of mutations or variants?
CLARIFIED ANSWER: Antigen test developers should identify the antigens used for generating antibodies and perform epitope mapping. They should analyze sequence data, translate it to amino acids, identify potential impacts of mutations, and conduct wet testing to assess impacts.
VERBATIM QUESTION: How can antigen test developers conduct in vitro testing for potential impacts of mutations or variants?
VERBATIM ANSWER: Antigen tests should know, you know, which antigen was used to generate their antibody or antibodies and epitope mapping information as well for those antibodies so that they can look at the sequence data. Translate it to amino acid and see were there are any potential impacts. And if there are potential impacts, there are various ways to test in vitro the impact of those mutations on antigen tests. And we would ask the developers for those mutations or variants that may impact their test to be able to do that testing. That would be wet testing, rather than in silico testing.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen test development, Variant impact testing, In vitro diagnostics
REVIEW FLAG: False

### removed qa blocks
QA Block 10-4
CLARIFIED QUESTION: Is the mentioned requirement for low positive samples a post-market commitment or part of pre-EUA submission?
CLARIFIED ANSWER: The FDA may require post-market commitments for low positive samples but advises submitting even if these samples are difficult to obtain for non-SARS targets.
VERBATIM QUESTION: Is the mentioned requirement for low positive samples a post-market commitment or part of pre-EUA submission?
VERBATIM ANSWER: So but, so we haven't in prior situations asked about that. So but we do have the flexibility to put in some commitments post-market. So I would not - if you're struggling to get those low positives for non-SARS targets, I would still submit and work with our team.
SPEAKER QUESTION: Rhina Vemon
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: post-market commitments, pre-EUA submission, low positive samples
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-03 19:49:42 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 12
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What factors are being studied to determine how serology tests measure immunity or protection?
QI 1-2: How can test developers independently generate data on the effectiveness of antibody levels in providing immunity?
QI 1-3: What is the current priority focus of the FDA for COVID-19 diagnostic test development?
QI 1-4: What is the FDA's recommendation for developers using the pre-EUA process?
QI 1-5: When might information from U.S. Government immunity and protection studies be available to the public?
QI 1-6: How does the FDA plan to address the significant backlog in the pre-EUA process?
QI 1-7: How can developers ensure their submissions align with the latest FDA recommendations and templates?

#### Section 2 of 12
##### Explicit Questions Extraction
QE 2-1: Once the COVID-19 emergency has been lifted, will FDA entertain the use of pooling in cleared FDA devices intended to detect SARS-CoV-2?
QE 2-2: Will FDA consider clearance for tests that are indicated for both individual and pooled specimen testing?
QE 2-3: Is it true that an over-the-counter molecular test should not include a hazardous substance?
QE 2-4: Does the restriction on hazardous substances for over-the-counter tests also apply to antigen tests, or just to molecular tests?

##### Implicit Questions Extraction
QI 2-1: What are acceptable forms of evidence or documentation to demonstrate that chemicals in a test are non-hazardous?
QI 2-2: What specific mitigation measures does the FDA recommend if a chemical in the test poses a potential but manageable safety risk?
QI 2-3: How are literature studies evaluated for determining the safety of chemicals at lower concentrations?
QI 2-4: What level of detail should be included in the submission of Material Safety Data Sheets (MSDS) for FDA review?
QI 2-5: What labeling requirements or recommendations does the FDA suggest for tests containing potentially hazardous substances?
QI 2-6: Does the FDA provide any guidance or examples of chemicals that have been deemed safe at low concentrations?

#### Section 3 of 12
##### Explicit Questions Extraction
QE 3-1: Will the FDA provide a template or guidance on an antibody level that demonstrates protection after vaccination to help healthcare providers track patient protection levels?

##### Implicit Questions Extraction
QI 3-1: What is the FDA's timeline for determining appropriate validation approaches for tests that monitor protection post-vaccination?
QI 3-2: Will the FDA consider issuing specific recommendations for interpreting positive or negative antibody test results for partially vaccinated individuals?
QI 3-3: What kind of alternatives can the Review Team suggest if developers struggle to collect sufficient positive and negative specimens?
QI 3-4: How should developers prioritize testing strategies while research on antibody correlations with protection is ongoing?

#### Section 4 of 12
##### Explicit Questions Extraction
QE 4-1: Would FDA consider reducing the sample sizes or requiring fewer samples for point of care COVID antibody test validations, given the challenges with dropping positivity rates and rising vaccination rates?
QE 4-2: What are the pre-EUA review timelines, and where can information about them be found?
QE 4-3: Does the FDA have a preference on the type of banked samples to use to supplement prospectively collected positive samples for molecular diagnostic tests, particularly for point of care tests?
QE 4-4: If pursuing a molecular diagnostic EUA for nasal swab samples, should sponsors test banked anterior nasal swabs, or would it be better to use banked nasopharyngeal swabs since nasopharyngeal swabs are considered the most challenging upper respiratory matrix?

##### Implicit Questions Extraction

#### Section 5 of 12
##### Explicit Questions Extraction
QE 5-1: What is expected from the antibody test regarding information about immunity to a vaccine?
QE 5-2: Do we have any tests for other infectious diseases that are approved by the FDA that work similarly?

##### Implicit Questions Extraction
QI 5-1: What are the specific situations where serology tests can be used in long COVID cases?
QI 5-2: What is the process to identify levels of antibodies that correlate with immunity to SARS-CoV-2?
QI 5-3: How can vaccine studies contribute to understanding antibody response and immunity over time?
QI 5-4: What additional data or studies are needed before serology tests can indicate reliable immunity to SARS-CoV-2?
QI 5-5: What would constitute a standardized correlative protection for SARS-CoV-2 similar to other vaccines?
QI 5-6: What is the timeline for establishing such a correlative protection for SARS-CoV-2?

#### Section 6 of 12
##### Explicit Questions Extraction
QE 6-1: Can the FDA connect our startup to COVID-19 test developers who might need a service to capture and report rapid test data since we have a deployable product for this purpose?
QE 6-2: Who should we talk to in order to make our rapid test data capture and reporting service available to test developers?

##### Implicit Questions Extraction

#### Section 7 of 12
##### Explicit Questions Extraction
QE 7-1: Does the FDA expect a similar distribution for retrospective influenza samples as it recommends for low viral load SARS-CoV-2 samples in the antigen template?
QE 7-2: How does the FDA characterize a low viral load influenza sample?

##### Implicit Questions Extraction
QI 7-1: What updates to the antigen template are currently being considered by the FDA?
QI 7-2: How should antigen test developers incorporate the recommendation for 20%-25% of samples being low positives within 3 CTs of the comparator assay's LoD?
QI 7-3: What are the expectations for evaluating low positives for other analytes, such as RSV, in multi-analyte respiratory panels?
QI 7-4: Are CT values for low positives in non-SARS-CoV-2 analytes like flu and RSV required to follow the same guidance as SARS-CoV-2?

#### Section 8 of 12
##### Explicit Questions Extraction
QE 8-1: What should we do if we receive irrelevant or accusatory questions from the reviewer during the antigen test review process?
QE 8-2: Who should we contact if the assigned reviewer does not respond to our follow-up questions about missing data?

##### Implicit Questions Extraction
QI 8-1: What details should be included in the email to the Templates email box regarding a submission issue?
QI 8-2: How can we ensure that submission issues are escalated appropriately within the FDA?
QI 8-3: Is it acceptable to directly address submission concerns to Dr. Stenzel or specific FDA representatives?
QI 8-4: What steps can a test developer take if they don't receive a response from their assigned reviewer?

#### Section 9 of 12
##### Explicit Questions Extraction
QE 9-1: Do you have enough personnel to do the review?
QE 9-2: Is the review process different from when applications were reviewed last year compared to when they are being reviewed now?
QE 9-3: Are low priority applications being reviewed with a different standard than applications considered high priority last year?
QE 9-4: Is the review process consistent compared to what was done previously?

##### Implicit Questions Extraction
QI 9-1: What are the criteria used to reprioritize paused, lower-priority COVID-19 test applications?
QI 9-2: What is the process for assigning paused applications to reviewers once backlog issues are alleviated?
QI 9-3: Do lower priority applications that were initially marketed through notification pathways require a secondary full review when revisited?
QI 9-4: What is the scope of the quick assessment process conducted when applications are first received?
QI 9-5: How are concerns identified during the quick assessment addressed before assigning an application to a reviewer?
QI 9-6: What specific communication should developers expect from reviewers when issues arise during the complete review phase?

#### Section 10 of 12
##### Explicit Questions Extraction
QE 10-1: What is the requirement for achieving a certain percentage of low positive samples in flu testing under the FDA guidance?
QE 10-2: Does the requirement for a percentage of low positive samples apply to molecular point of care tests?
QE 10-3: Can banked flu samples with potentially limited positivity distribution be used to meet FDA submission requirements for flu A/B and COVID-19 tests?
QE 10-4: Is the mentioned requirement for low positive samples a post-market commitment or part of pre-EUA submission?

##### Implicit Questions Extraction
QI 10-1: What level of flexibility does the FDA have when evaluating new panel tests under EUA?
QI 10-2: Can banked samples with uneven positivity distributions still be used in EUA submissions during times of low clinical sample availability?
QI 10-3: Will the FDA make post-market commitments to address the requirement for low positive samples in cases where they are not available during pre-submission?
QI 10-4: Is the low positive requirement applicable to non-SARS targets in panel tests for EUA?

#### Section 11 of 12
##### Explicit Questions Extraction
QE 11-1: Can you expand on the apparent contradiction between CDC's guidelines on vaccinated individuals not needing masks and the lack of correlation between antibody titer and immunity?

##### Implicit Questions Extraction

#### Section 12 of 12
##### Explicit Questions Extraction
QE 12-1: Is the FDA reference panel required only for molecular tests or is there also a panel for antigen tests?
QE 12-2: Is the inclusivity analytical sensitivity performance study required only for molecular tests?

##### Implicit Questions Extraction
QI 12-1: What challenges prevent the FDA from producing a reference panel for antigen tests?
QI 12-2: Why is in silico inclusivity testing challenging for antigen tests?
QI 12-3: What specific steps should developers take to monitor variants and mutations impacting test performance?
QI 12-4: What information about antigens and antibodies is necessary for antigen test developers?
QI 12-5: How can antigen test developers conduct in vitro testing for potential impacts of mutations or variants?
